Tao Capital Partners
VC Fund
San Francisco, United States
Tao Capital Partners is a VC fund in San Francisco focused on Biotechnology and Software. Tao Capital Partners invests in technology, transportation, healthcare, education, and food businesses that have a sustainable positive impact. It is an active investor that supports companies through various stages of their life-cycle. Tao Capital Partners was founded in 2002 and is based in San Francisco, California.
- Total investments:
- 105
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Tao Capital Partners invests in
BiotechnologySoftwareHealth CareManufacturingSaaS
Stages Tao Capital Partners invests in
Series BSeries CSeries ASeries DFunding Round
Countries Tao Capital Partners invests in
United StatesChinaSpain
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Isaac Pritzker
|
|||
Joby Pritzker
|
|||
|
Steve Tracy
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 17 (16%)
- Software 12 (11%)
- Health Care 12 (11%)
- Manufacturing 10 (10%)
- SaaS 7 (7%)
Stage
- Series B 28 (27%)
- Series C 17 (16%)
- Series A 15 (14%)
- Series D 12 (11%)
- Funding Round 10 (10%)
Country
- United States 53 (50%)
- China 1 (1%)
- Spain 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Isaac Pritzker
Investor
|
Investor | Total investments: 2 | Find email | |
|
Joby Pritzker
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Steve Tracy
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Loop
|
Loop provides a platform that manages logistics and supply chain data through automation and analytics tools. The system aggregates shipment, carrier, and financial data into a unified interface to support visibility and coordination. It includes features for freight audit, payment processing, and cost tracking across transportation activities. Theplatform also supports issue resolution, reporting, and performance monitoring for carriers and shipments. Loop serves organizations that require structured data handling and process automation within logistics operations. | $95M / Series C / Apr 17, 2026 | |
Ripple Foods
|
Ripple Foods specializes in making non-dairy milk with just as much protein as milk and half the sugar. Ripple has 8x the protein of almond milk and half the sugar of dairy milk. It’s high in bioavailable calcium (50% more than milk), potassium and provides a good source of omega-3s. It’s lower in calories than milk and best of all, it has thecreamy, delicious texture our dairy-free friends are missing. No more thin, chalky almond/ soy/ cashew milk.It was founded in 2014 and headquartered in Emeryville, California. | $17M / Dec 02, 2025 | |
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | |
Elephas
|
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodalmicroscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development. | $40M / Venture - Series Unknown / Nov 06, 2025 | |
Atlas Data Storage
|
Atlas Data Storage develops data storage systems utilizing synthetic DNA to encode digital information. The company offers end-to-end solutions that integrate semiconductor-based synthesis and enzyme engineering to store data in DNA strands. This approach aims to provide long-term, high-density storage options for various sectors. Atlas DataStorage's technology is designed to address the growing demand for scalable and energy-efficient data storage solutions. | $155M / Seed / May 05, 2025 | |
AMP
|
AMP’s AI-driven waste sorting solutions help optimize material recovery and recycling processes. Our waste sorting machines use real-time material characterization and high-speed sortation to increase resource recovery. As a waste sorting manufacturer, we deliver automated sortation services to enhance efficiency and reduce costs. Our technologysupports plastic waste management services, fiber waste management services, metal waste management services, film waste management services, and single-stream waste management services. From MSW management services to e-waste management services, we help facilities maximize recovery rates and minimize contamination. Machining manufacturer expertise with AI-driven automation makes us a leader in waste recycling manufacturing. Get in touch to explore how we can optimize your facility. | $91M / Series D / Dec 05, 2024 | |
Vizgen
|
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. | Series D / Oct 09, 2024 | |
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Jul 17, 2024 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Series D / Jul 17, 2024 | |
Quantum Circuits
|
Quantum Circuits, Inc. (QCI) is a private venture founded in late 2015. QCI’s long-term goal is to develop, manufacture, and sell the first practical and useful quantum computers based on superconducting devices. Along the way to building a quantum computer, QCI will commercialize the components, devices, and software that will accelerate basicresearch and enable the scaling of quantum computing.“Quantum circuits” has a double meaning. First, the name indicates that QCI is focusing on the quantum circuit model for quantum computation, which enables universal and fault-tolerant operations using error correction. Second, our technology relies on quantum circuits – electrical devices using superconducting Josephson junctions that can act as solid-state quantum bits, or qubits.QCI was founded by three scientists from the Department of Applied Physics at Yale University: Michel Devoret, Luigi Frunzio, and Robert Schoelkopf. They are world-leading experts in quantum devices and quantum information processing with solid-state devices, with a decades-long record of innovation in new devices, techniques, and fundamental concepts. Their group has produced many scientific firsts, including the development of a “quantum bus” for entangling qubits with wires, the first implementation of a quantum algorithm with a solid-state device, and the demonstration of solid-state qubits with scalable levels of coherence. | $60M / Series B / May 01, 2024 | |
| See all 105 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Tao Capital Partners invest in?
Tao Capital Partners invests primarily in Biotechnology, Software and Health Care startups, most often at Series B and Series C stage. Most of the 105 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tao Capital Partners?
Public channels for Tao Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tao Capital Partners?
The team at Tao Capital Partners includes Isaac Pritzker (Investor), Joby Pritzker (Managing Director) and Steve Tracy (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
